NO20064874L - Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme - Google Patents

Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme

Info

Publication number
NO20064874L
NO20064874L NO20064874A NO20064874A NO20064874L NO 20064874 L NO20064874 L NO 20064874L NO 20064874 A NO20064874 A NO 20064874A NO 20064874 A NO20064874 A NO 20064874A NO 20064874 L NO20064874 L NO 20064874L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
release pharmaceutical
controlled release
preparation
same
Prior art date
Application number
NO20064874A
Other languages
English (en)
Inventor
Takashi Yoshitake
Mitsuru Mizuno
Kenji Moroshima
Shigeru Aoki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20064874L publication Critical patent/NO20064874L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Det er en hensikt ved den foreliggende, oppfinnelsen i forbindelse med en farmasøytisk sammensetning med kontrollert frigjøring, da spesielt en farmasøytisk med pulserende frigjøring, og som inneholder et syreustabilt fysiologisk aktivt stoff å tilveiebringe en farmasøytisk sammensetning med liten variasjon i oppløsningsforsinkelsestid og meget pålitelige oppløsningsegenskaper. Den foreliggende oppfinnelsen beskriver en farmasøytisk sammensetning med kontrollert frigjøring som omfatter (1) en kjerne som inneholder et syreustabilt fysiologisk aktivt stoff og et nedbrytningsmiddel og (2) et frigjøringskontrollerende lag som dekker kjernen og som inneholder en vannuløselig polymere, en enterisk polymer og en hydrofob voks.
NO20064874A 2004-03-26 2006-10-26 Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme NO20064874L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004093506 2004-03-26
PCT/JP2005/005217 WO2005092336A1 (ja) 2004-03-26 2005-03-23 溶出制御製剤とその製造方法

Publications (1)

Publication Number Publication Date
NO20064874L true NO20064874L (no) 2006-12-19

Family

ID=35055974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064874A NO20064874L (no) 2004-03-26 2006-10-26 Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme

Country Status (17)

Country Link
US (2) US20080095839A1 (no)
EP (1) EP1728512A1 (no)
JP (1) JPWO2005092336A1 (no)
KR (1) KR100794078B1 (no)
CN (1) CN1938026A (no)
AU (1) AU2005225283B2 (no)
BR (1) BRPI0509135A (no)
CA (1) CA2557791C (no)
IL (1) IL177087A (no)
MX (1) MXPA06010785A (no)
MY (1) MY139427A (no)
NO (1) NO20064874L (no)
NZ (1) NZ549838A (no)
RU (1) RU2337687C2 (no)
TW (1) TW200602085A (no)
WO (1) WO2005092336A1 (no)
ZA (1) ZA200607603B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
MXPA06010785A (es) * 2004-03-26 2007-03-28 Eisai R&D Man Co Ltd Composicion farmaceutica de liberacion controlada y metodo para producir la misma.
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
EP1872778A1 (en) * 2006-06-29 2008-01-02 LEK Pharmaceuticals D.D. Stable pharmaceutical composition with rabeprazole sodium
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
WO2008015530A2 (en) * 2006-08-03 2008-02-07 Aurobindo Pharma Limited Stable solid oral formulation of pantoprazole
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
MX336789B (es) 2007-08-13 2016-02-02 Inspirion Delivery Technologies Llc Farmacos resistentes al abuso, metodo de uso y metodo de fabricacion.
JP4864024B2 (ja) * 2008-02-15 2012-01-25 エスエス製薬株式会社 時限放出製剤
JP2009191036A (ja) * 2008-02-15 2009-08-27 Ss Pharmaceut Co Ltd 時限放出製剤
JP2009191034A (ja) * 2008-02-15 2009-08-27 Ss Pharmaceut Co Ltd 時限放出製剤
EP2255794A1 (en) * 2009-05-29 2010-12-01 H e x a l Aktiengesellschaft Enteric coating
JP5503192B2 (ja) * 2009-06-03 2014-05-28 大原薬品工業株式会社 生理活性物質含有粒子の製造方法
JP2013500280A (ja) * 2009-07-30 2013-01-07 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング アニオン性ポリマー材料と６〜２２個の炭素原子を有する飽和モノカルボン酸の塩とを含む組成物
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
JP2014122328A (ja) * 2012-11-22 2014-07-03 Shin Etsu Chem Co Ltd 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法
CA2907428A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
CN103976972B (zh) * 2014-05-26 2017-09-12 中国药科大学 酒石酸唑吡坦口服脉冲控释给药系统及其制备方法
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US20190008787A1 (en) 2015-07-17 2019-01-10 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
EP3117824A1 (en) 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
CN105796532B (zh) * 2016-03-28 2018-12-21 中国医药集团总公司四川抗菌素工业研究所 一种雷贝拉唑钠缓释胶囊及其制备方法
KR20210071242A (ko) * 2019-12-06 2021-06-16 진양제약주식회사 제약 조성물
CN113069428B (zh) * 2021-04-02 2023-02-10 珠海润都制药股份有限公司 一种雷贝拉唑钠肠溶片的制备方法
KR102647279B1 (ko) 2021-04-08 2024-03-18 대한뉴팜(주) 라베프라졸의 우수한 방출 특성을 갖는 라베프라졸 나트륨 및 산화마그네슘을 포함하는 제제 및 이의 제조방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US6156343A (en) * 1994-12-27 2000-12-05 Akzo Nobel N.V. Controlled release preparation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
CA2587022A1 (en) * 1998-05-18 1999-11-25 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
US6174902B1 (en) * 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
JP2001055322A (ja) * 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd パルス放出型製剤
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7220762B1 (en) * 1999-10-20 2007-05-22 Eisai R&D Management Co., Ltd. Methods for stabilizing benzimidazole compounds
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
WO2003043661A1 (fr) 2001-11-21 2003-05-30 Eisai Co., Ltd. Compositions de preparation contenant des composes actifs au plan physiologiques et instables aux acides et leur procede de production
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
EA006008B1 (ru) * 2002-04-29 2005-08-25 Эгиш Дьёдьсердьяр Рт. Способ получения таблеток из фармацевтически активных веществ
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
MXPA06010785A (es) * 2004-03-26 2007-03-28 Eisai R&D Man Co Ltd Composicion farmaceutica de liberacion controlada y metodo para producir la misma.
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤

Also Published As

Publication number Publication date
US20080095839A1 (en) 2008-04-24
WO2005092336A1 (ja) 2005-10-06
ZA200607603B (en) 2007-05-30
JPWO2005092336A1 (ja) 2008-02-07
KR100794078B1 (ko) 2008-01-10
AU2005225283B2 (en) 2008-09-18
IL177087A (en) 2011-11-30
KR20060134124A (ko) 2006-12-27
BRPI0509135A (pt) 2007-08-28
US20070110806A1 (en) 2007-05-17
CA2557791C (en) 2011-03-08
TW200602085A (en) 2006-01-16
EP1728512A1 (en) 2006-12-06
MY139427A (en) 2009-09-30
AU2005225283A1 (en) 2005-10-06
NZ549838A (en) 2010-04-30
IL177087A0 (en) 2006-12-10
MXPA06010785A (es) 2007-03-28
RU2006134052A (ru) 2008-04-10
RU2337687C2 (ru) 2008-11-10
CN1938026A (zh) 2007-03-28
US20120003311A9 (en) 2012-01-05
CA2557791A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
NO20064874L (no) Kontrollert frigivelses farmasoytisk sammensetning og metode for fremstilling av samme
AU2004208606B2 (en) Process for producing coated preparation
CA2348086C (en) Controlled-release pharmaceutical formulations
RU99126869A (ru) Фармацевтический препарат омепразола
RU2006101082A (ru) Фармацевтическая композиция с набухающим покрытием
CA2625554C (en) Enteric soft capsule comprising valproic acid
NO330144B1 (no) Gastrobeskyttede omeprazolmikrogranuler, fremgangsmate for a oppna slike og farmasoytiske preparater
WO2008085484A3 (en) Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
AR038157A1 (es) Formas de dosificacion de benzimidazoles sustituidos y su uso
PL356962A1 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
NO20075404L (no) Tablett inneholdende steroidhormoner
EP2046305A2 (en) Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
NO20092662L (no) Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme
CA2566497A1 (en) Multi-layered controlled-release methylphenidate pellet
GEP20043285B (en) Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
MX2007004986A (es) Nuevas formulaciones de pelotillas de liberacion modificada para inhibidores de bomba de protones.
CA2595409A1 (en) Oral dosage form comprising rosiglitazone
WO2009090484A3 (en) Mesalazine tablet
DE60211769D1 (de) Verfahren zur Herstellung von Arzneistoffgranulatkörnern, die Arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische Zubereitungen
KR20100008356A (ko) 칼슘채널길항제를 포함하는 약제학적 제제
JP2019509345A5 (no)
AU2017304029A1 (en) Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
NO20052960L (no) Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi
NO331643B1 (no) Mikrogranuler som ikke er loselige i magesaft, fremgangsmater for a oppna det samme og farmasoytiske preparater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application